🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — June 29, 2026

Today's 50 filings paint a picture of a market bifurcated between capital-constrained micro-caps facing existential threats and a massive, coordinated corporate action by the AllianceBernstein fund complex. The dominant theme is the Equitable-Corebridge merger, which triggers across 17 AB funds the need for new investment advisory agreements, creating a significant but non-economic administrative catalyst. In contrast, several micro-cap companies (Capstone, Picard Medical, Boxlight) are in acute distress, racing against Nasdaq delisting deadlines and relying on dilutive financing to stay afloat. However, selective opportunities exist: AstraZeneca's positive CHMP opinion for a new TNBC therapy signals a high-impact commercial catalyst, while VivoPower's selection of a global AI leader for its Norwegian data center and Decoy Therapeutics' institutional PIPE point to high-conviction bets in AI infrastructure and biotech, respectively. Overall, the digest shows a 'haves and have-nots' dynamic, with strong capital flows toward select growth stories and a punishing environment for companies with weak balance sheets.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — June 29, 2026

The two S&P 500 Healthcare filings today (ABBOTT LABORATORIES and CVS Health Corp) are both routine Form 4 filings related to tax withholding on restricted stock vesting, with no material new strategic or financial disclosures. The insider transactions are non-discretionary and carry neutral sentiment, indicating no management conviction signals. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity were reported in these filings. The overall sector pulse remains stable with no immediate catalysts or red flags from this batch. Investors should focus on upcoming earnings calls and broader sector trends for actionable insights.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — June 29, 2026

This digest covers 35 filings, heavily tilted toward early-stage and micro-cap companies, with 9 SPACs, shell companies, or entities with no revenue. A clear sector-level pattern is the divergence between two defensive growth areas: insurance brokerage (QDM International, +28.5% revenue) and diabetes tech (PodcastOne, +18.4% revenue; MiniMed, +14.2% revenue), which show strong top-line momentum and improving unit economics. In contrast, energy E&P (Mexco Energy, -8.0% revenue) and security services (AmeriGuard, -11.1% revenue) are contracting. The most critical development is the dramatic turnaround in commercial metals (CMC, net earnings +108% YoY) driven by M&A, but funded with a 270% surge in interest expense, creating a potential debt risk. Across the sample, the crypto trusts (Franklin Solana, Franklin XRP, 21Shares Polkadot) are a red flag, all reporting large unrealized losses and net asset erosion despite massive capital inflows, signaling a 'value trap' in the digital asset space. Notably, cash burn is a systemic theme: 7 out of 10 companies with detailed cash flow data saw operating cash flow decline or turn negative, including AeroVironment (-$265M net loss, goodwill impairment) and Replimune (-$280M cash used, +46% YoY). Insider activity is sparse, but the few signals (like the SPAC share surrenders at Patriot Acquisition) point to dilution-avoidance maneuvers rather than confidence. The capital allocation landscape is bifurcated: Lennar repaid $736.8M in buybacks and $246.5M in dividends, signaling a mature capital return model, while growth names like Elite Pharmaceuticals (R&D -28% YoY) and AeroVironment (SG&A +179% YoY) are shifting spending from R&D to G&A, a bearish mix.

35 high priority 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — June 29, 2026

This batch of 17 proxy filings reveals a market bifurcated between capital-intensive SPACs and micro-caps facing existential liquidity crises, and a handful of stable, cash-generating businesses returning value to shareholders. The most critical theme is the wave of SPAC liquidations and reverse stock splits: Compass Digital Acquisition Corp. is on the brink of liquidation with a negative trust-to-market arbitrage, Picard Medical and Transportation & Logistics Systems are pursuing desperate reverse splits to maintain exchange listings, and M3-Brigade Acquisition V is scrambling for a 12-month extension after a failed deal. In contrast, Prestige Consumer Healthcare is executing a disciplined acquisition strategy with strong free cash flow, while Aura Biosciences is aggressively diluting shareholders to fund growth, signaling high cash burn. Insider trading activity is notably absent across the filings, suggesting a lack of conviction or a wait-and-see approach from management. The forward-looking calendar is packed with critical shareholder votes in July and August 2026, creating a high-stakes catalyst window for event-driven investors. Overall, the portfolio is dominated by governance and survival votes, with limited organic growth signals, making this a high-risk, event-driven environment.

17 high priority 17 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 29, 2026

The IPO pipeline is active with 10 filings, including 4 traditional IPOs (Forgent Power Solutions, SeeQC, Exyn Technologies, Ionic Digital), 3 S-1 resale registrations (Capstone Holding, Classover Holdings, BiomX), 2 S-4 merger registrations (Equity Residential, FS Bancorp), and 1 follow-on offering (Capstone Holding second filing). Key themes include high dilution risk from resale registrations and equity lines, mixed financial health with revenue growth but net losses, and significant insider activity absent in most filings. The most critical developments are Forgent Power Solutions' IPO with 7.1% revenue growth but a net loss swing, Ionic Digital's direct listing with no lock-ups, and FS Bancorp's accretive bank merger. Portfolio-level patterns show a tilt toward pre-revenue or loss-making companies in emerging tech (quantum, drones, biotech-defense), while traditional sectors (REITs, banks) show stability. Period-over-period trends reveal revenue growth in Forgent (7.1% YoY) and backlog expansion, but margin compression in BiomX and Capstone due to restructuring costs.

10 high priority 10 total filings
· daily

US Executive Officer Management Changes SEC — June 29, 2026

Today's 32 filings reveal a landscape of leadership realignment driven by strategic succession planning and the unlocking of value via spin-offs. The most significant trend is a wave of CFO transitions at mid-cap companies (Genesco, Freedom Holding, TransAct Technologies, Tenaya Therapeutics), signaling a focus on financial stewardship for growth. A parallel theme involves companies like Corteva and Fortune Brands Innovations using board appointments and CEO changes to drive separation strategies and operational turnarounds. While overall sentiment is predominantly neutral, the insider activity is minimal but positive, with companies like Swarmer and Pinnacle West rewarding executives with salary increases and retention awards, indicating confidence in their strategic direction. Notable risks emerge from massive potential dilution at Synergy CHC and a pattern of director departures without disagreement at several smaller firms, suggesting normal governance churn rather than distress. Opportunities exist in the new leadership at Tenaya Therapeutics and the strategic board enhancements at MiniMed Group and ITT Inc., which bring deep industry expertise to catalyze growth.

32 high priority 32 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 29, 2026

This digest reveals a bifurcated corporate landscape on June 29, 2026, where aggressive M&A and financing activity (e.g., Martin Marietta's $13.5B acquisition, Rocket Lab/Iridium $8B merger) coexists with acute distress signals from micro-cap companies resorting to dilutive offerings and asset sales. The most critical theme is the 'cash-for-survival' pattern: multiple distressed entities (Volato, Datavault AI, U.S. GoldMining) are executing deeply dilutive financings or selling digital assets at a loss to stave off insolvency, while healthier firms are using cheap debt to consolidate. A notable period-over-period trend is the compression of margins in capital-intensive sectors (Honeywell Aerospace Q4 net income down 25% YoY) contrasted with high-margin recurring revenue models (Iridium's 57% OEBITDA margin). Insider activity is sparse but telling, with director resignations at Volato signaling governance risk. The forward-looking catalyst calendar is dense with Q3 2026 merger closes (TOMI/Carbonium, SandRidge, Martin Marietta) and a major mid-2027 close for the Rocket Lab/Iridium deal, creating a 12-month arbitrage window. The overarching takeaway: the market is rewarding scale and recurring cash flow while punishing companies with weak balance sheets and no clear path to profitability.

45 high priority 45 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 29, 2026

The 32 filings from June 29, 2026, reveal a significant wave of board and C-suite changes across US-listed companies, with a notable focus on CFO transitions and strategic board refreshment. Key themes include a high volume of CFO appointments (Genesco, TransAct Technologies, Freedom Holding Corp, Tenaya Therapeutics) and departures (Cadrenal Therapeutics, PEDEVCO), often tied to strategic pivots toward digital growth or SaaS platforms. Insider activity is limited but includes a large discretionary credit award to a Pinnacle West executive and significant salary increases at Swarmer, suggesting management confidence in those firms. Forward-looking data points to a major corporate separation at Corteva (Q4 2026) and a pending merger at Columbia Financial. Several companies are advancing gene therapy or medical device programs, while others face potential dilution or Nasdaq compliance risks, as flagged by Synergy CHC's massive equity plan and reverse split authorization. Overall, the period is characterized by active governance restructuring, with a mix of bullish signals from new leadership and bearish risks from shareholder dissent and executive departures.

32 high priority 32 total filings
· daily

USA Insider Trading Pulse — June 29, 2026

Today's insider trading pulse reveals a pronounced divergence between heavy insider selling at Chinese ADRs (Alibaba, Sea Ltd, UP Fintech) and significant insider buying at deeply discounted micro-cap and special situation names (CalciMedica, Hammer Technology, MODIV Industrial). The Alibaba CFO's $2.13M sale stands out as the largest single insider disposition, while Hammer Technology's CEO deployed $2.68M at $0.26/share, signaling extreme conviction in a turnaround. A notable cluster of option exercises at Brazilian Electric Power Co (Eletrobras) suggests management is monetizing long-term equity grants, likely tied to the company's privatization and restructuring. TTM Technologies saw coordinated selling by five executives under 10b5-1 plans, indicating pre-planned portfolio diversification rather than a negative signal. The overall theme is one of insider caution at larger-cap growth names versus opportunistic buying at distressed levels, with 10b5-1 plans providing cover for much of the selling activity.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 29, 2026

This U.S. M&A and takeover digest spans 11 filings, with a heavy concentration of SPAC activity alongside significant corporate transformations and asset acquisitions. The most critical development is Honeywell's completion of its Aerospace Technologies spin-off, a major strategic pivot that creates three independent, focused leaders and is expected to unlock substantial shareholder value through a pure-play structure. The period also saw a landmark transaction in the real assets management sector, where CIM Real Estate Finance Trust acquired CIM Group's business in a deal that values the combined entity's assets at over $30 billion, though existing CMFT shareholders were diluted to a 32.5% stake. Another notable M&A theme is the trend of early-stage biotech de-SPACs, exemplified by Talawar Therapeutics' merger with JATT II Acquisition Corp, which is bolstered by a massive $285 million in proceeds including an oversubscribed $225 million PIPE. On the lower end of the materiality spectrum, several SPACs are merely extending deadlines or completing administrative steps, such as unit separations, reflecting a challenging environment for finding viable targets. Blue Owl's acquisition of a data center facility in Virginia underscores the growing appetite for digital infrastructure assets. A significant risk flag is raised by Acura Pharmaceuticals, whose debt load has ballooned by 361% since 2022, indicating severe financial distress. Overall, the quarter ended with a clear bifurcation: high-conviction, well-capitalized M&A (Honeywell, Talawar/JATT, Blue Owl) versus capital-constrained, deadline-driven SPACs (CSTAF, Alpex).

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 29, 2026

Overnight SEC filings from June 28-29, 2026, reveal a market bifurcated between aggressive capital raises and defensive restructuring. A dominant theme is the wave of dilutive equity offerings from small-cap and micro-cap companies, including Capstone Holding, Creative Realities, U.S. GoldMining, Volato Group, and Decoy Therapeutics, signaling acute cash needs and high dilution risk for existing shareholders. In contrast, Realty Income disclosed a robust $4.0 billion liquidity position, highlighting the divergence in capital access. The healthcare sector shows a bright spot with AstraZeneca's positive CHMP opinion for a new breast cancer therapy, a significant catalyst. A massive administrative event is the Equitable-Corebridge merger, which is triggering a coordinated proxy solicitation across 17 AllianceBernstein funds to approve new advisory agreements, creating a non-economic but administratively critical vote on August 3, 2026. Several companies, including Picard Medical and Boxlight, are pursuing reverse stock splits to address exchange listing deficiencies, a recurring distress signal. Overall, the period is characterized by capital structure stress, regulatory catalysts, and a significant fund-level administrative event.

12 high priority 38 medium 50 total filings
· daily

Biodefense & Pandemic Preparedness — June 28, 2026

This digest covers a single, high-value contract from the Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc. (Emergent Biosolutions) for the ACAM2000 smallpox vaccine, totaling $857.6 million over a potential 10-year period (2019-2029). The contract is entirely civilian (HHS/ASPR) with no defense-related component, and the aggregate obligation is $857.6 million with a strong average signal strength of 8.0/10. The highest-conviction signal is the bullish revenue visibility from this firm fixed-price contract, which has already outlayed $457.9 million, indicating strong government demand. Key risks include execution risk from the fixed-price structure and potential program delays if outlay pace slows, as well as dependency on future congressional appropriations for HHS/ASPR biodefense programs.

1 total filings
· daily

Federal Construction & Infrastructure Contracts — June 28, 2026

This digest covers a single, massive $1.31 billion civilian contract awarded to SLS Federal Services LLC by the Department of Homeland Security (DHS) on June 26, 2026. The award is a high-materiality, bullish signal for SLS Federal Services, but its sole-source nature and lack of pricing or competitive detail introduce execution and budget risks. As a civilian agency contract, it is not directly tied to NDAA durability, but DHS infrastructure spending remains a policy priority. The key watch item is the absence of contract vehicle type (fixed-price vs. cost-plus) and the potential for protest or budget reallocation under a continuing resolution.

1 total filings
· daily

DHS Homeland Security Contracts — June 28, 2026

A single $1.31B sole-source contract from the Department of Homeland Security to SLS Federal Services LLC dominates the period, representing 100% of total obligation. This is a civilian agency award, not defense-related, signaling a major DHS modernization or operational support program. The high materiality score (8/10) and bullish signal (7/10) suggest a durable, high-value program, but the lack of pricing details and competition data introduces execution and budget risk. Investors should watch for follow-on task orders or protests that could disrupt SLS Federal Services' revenue stream.

1 total filings
· daily

New Federal Contractors — June 28, 2026

The June 28, 2026, digest covers $2.51B in total obligations, with a stark 1:2 defense-to-civilian split. The dominant agency is the Department of Health and Human Services (HHS), accounting for $1.20B across two contracts, reinforcing a civilian biodefense and healthcare administration theme. The highest-conviction signal is a $857.6M firm fixed-price contract for Emergent BioSolutions’ ACAM2000 smallpox vaccine, offering long-term revenue visibility through 2029 but with medium execution risk. A key risk is the negative outlay (-$762k) on a $339.5M CMS contract with CGS Administrators, which may indicate early-stage underperformance or termination. The remaining $1.31B from DHS was awarded to SLS Federal Services but lacks pricing and competition detail, limiting conviction.

3 total filings
· daily

Significant Contract Modifications ($10M+) — June 28, 2026

The three contracts total $2.51 billion, with a 2:1 civilian-to-defense split by value. The dominant theme is civilian biodefense and health administration, led by a $1.31B DHS award to SLS Federal Services LLC and an $857.6M HHS/ASPR contract to Emergent Biosolutions for the ACAM2000 smallpox vaccine. The highest-conviction signal is the Emergent contract, which provides long-term revenue visibility through 2029, though execution risk is elevated due to its firm fixed-price structure. A key risk is the negative outlay (-$762K) on the CGS Administrators CMS contract, which may indicate program delays or termination risk. No defense-specific contracts were identified beyond the DHS award, limiting defense sector exposure in this digest.

3 total filings
· daily

Contract Deobligations Alert — June 28, 2026

This digest covers $2.51 billion in total obligations across three contracts, with a heavy civilian tilt (two HHS awards totaling $1.20 billion) and one DHS defense-related award of $1.31 billion. The highest-conviction signal is Emergent Biosolutions' $857.6 million firm fixed-price contract for the ACAM2000 smallpox vaccine, offering long-term revenue visibility through 2029 but with execution risk due to fixed-price cost burden. The DHS award to SLS Federal Services LLC is a large, opaque sole-source-like signal with limited public data, warranting caution. A key risk is the negative outlay on CGS Administrators' CMS contract, which may indicate program underperformance or termination. Investors should watch for option exercises on Emergent's contract and any follow-on awards from CMS for health insurance administration.

3 total filings
· daily

Contract Option Exercises — June 28, 2026

The three contract option exercises analyzed, totaling $2.51 billion, are overwhelmingly civilian-focused with a notable biodefense theme, as the Department of Health and Human Services accounts for $1.2 billion (48%) of the aggregate. The highest-conviction signal is Emergent Biosolutions' $857.6 million firm fixed-price ACAM2000 smallpox vaccine contract, which provides decade-long revenue visibility ($85.8M annualized) but carries execution risk due to the fixed-price structure. A critical risk is the $339.5 million CMS contract with CGS Administrators exhibiting a negative outlay (-$762k), potentially signaling program delays or termination risk. The sole defense contract, a $1.31 billion DHS award to SLS Federal Services, lacks pricing details and competitive moat data, limiting its actionable investment value despite its large size.

3 total filings
· daily

All HHS Contracts — June 28, 2026

The two HHS contracts reviewed total $1.197 billion in obligations, with a clear civilian agency focus (no direct defense contracts), though one award is categorized as defense-related due to its biodefense product. The dominant theme is pandemic preparedness and strategic health insurance administration, with Emergent Biosolutions’ $857.6 million ACAM2000 smallpox vaccine contract serving as the highest-conviction signal, offering long-term revenue visibility into 2029. However, the sizable $457.9 million outlayed balance signals strong government commitment, while execution risk from the firm fixed-price structure is notable. CGS Administrators’ $339.5 million CMS contract is neutral and private, offering no direct public equity exposure. Key watch items include Emergent’s outlay pace and contract re-compete dates, as well as CMS budget stability for follow-on awards.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 28, 2026

The three contracts totaling $2.51 billion present a bifurcated investment story: a dominant $1.31 billion DHS award to SLS Federal Services LLC (defense-related, bullish) and two civilian HHS contracts—a $857.6 million Emergent Biosolutions smallpox vaccine deal (bullish, high materiality) and a $339.5 million CMS contract to private CGS Administrators (neutral, low materiality). The highest-conviction signal is Emergent Biosolutions' long-term revenue visibility from a firm fixed-price biodefense contract, but execution risk is medium due to pricing structure. Key risk: the CGS contract shows negative outlays (-$762K), suggesting potential underperformance or termination risk. The defense/civilian split is 1:2 by count but 52%/48% by value, with civilian biodefense and healthcare administration dominating.

3 total filings